-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 9th, CDE's official website revealed that Colum Pharmaceuticals had submitted a listing application for the Sidine acid sourdino non-mouth-crash tablet", the first in the country to be reported for the dosage form.
, which was approved by the FDA on March 27, 1998, became the first ED first-line drug to treat ED's phosphatase-5 (PDE-5) inhibitor.
was approved for the NMPA on December 26, 2019, and is primarily a new option for patients with dysphagia or difficulties, as well as patients with erectile dysfunction who have difficulty accessing water.
Insight database shows that there are currently seven companies listed in China, including the original research Pfizer "Van Aico", Baiyunshan "Kingo", Abang Epson "Wan Feile", Changshan Bio-Chemical "Wanyeqiang", Chengdu Geopharma "Aogo", Jilin Jinheng "Ligo" and this year just approved Qilu Pharmaceuticals.
public data show that in 2019, the top three non-market share companies in China are Baiyunshan 48.1%, Pfizer 46.9% and Abang Epson 3.7%.
in the just-concluded third batch of collections, Sidna non-competition wonderful, Qilu Pharmaceuticals with a high level of quotation level PK dropped all competitors winning the bid, exclusive supply throughout the country.
In the field of men's drug use, Colum has previously successfully taken Dapostin tablets for the treatment of men's premature ejaculation (PE), "Valdina non-tablets" for male erectile dysfunction, for Sidinafei also take the layout of the small group of pills, Colum is bound to be in the male health drug market.
Insight database shows that there are currently few domestic companies layout of West Dina non-mouth-breaking tablets, Dr. Reddy of India in 2017 to submit a generic drug market application in China, 2018 shows that the batch is not expected to be approved.
Pharmaceuticals is the first company in China to complete the human bioethics test after the listing, is expected to win the first imitation.
.
